Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia.
Tiong IS, Dillon R, Ivey A, Kuzich JA, Thiagarajah N, Sharplin KM, Kok CH, Tedjaseputra A, Rowland JP, Grove CS, Abro E, Shortt J, Hiwase DK, Bajel A, Potter NE, Smith ML, Hemmaway CJ, Thomas A, Gilkes AF, Russell NH, Wei AH. Tiong IS, et al. Among authors: kok ch. Blood Adv. 2021 Dec 14;5(23):5107-5111. doi: 10.1182/bloodadvances.2021005455. Blood Adv. 2021. PMID: 34555849 Free PMC article.
Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML.
Powell JA, Thomas D, Barry EF, Kok CH, McClure BJ, Tsykin A, To LB, Brown A, Lewis ID, Herbert K, Goodall GJ, Speed TP, Asou N, Jacob B, Osato M, Haylock DN, Nilsson SK, D'Andrea RJ, Lopez AF, Guthridge MA. Powell JA, et al. Among authors: kok ch. Blood. 2009 Nov 26;114(23):4859-70. doi: 10.1182/blood-2009-02-204818. Epub 2009 Oct 5. Blood. 2009. PMID: 19805619 Free article.
TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.
Nievergall E, Reynolds J, Kok CH, Watkins DB, Biondo M, Busfield SJ, Vairo G, Fuller K, Erber WN, Sadras T, Grose R, Yeung DT, Lopez AF, Hiwase DK, Hughes TP, White DL. Nievergall E, et al. Among authors: kok ch. Leukemia. 2016 Jun;30(6):1263-72. doi: 10.1038/leu.2016.34. Epub 2016 Feb 22. Leukemia. 2016. PMID: 26898188 Clinical Trial.
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills AK, Filshie RJ, Arthur CK, Dang P, Saunders VA, Braley J, Yong AS, Yeung DT, White DL, Grigg AP, Schwarer AP, Branford S, Hughes TP; Australasian Leukaemia and Lymphoma Group (ALLG). Ross DM, et al. Among authors: kok ch. Leukemia. 2018 Dec;32(12):2572-2579. doi: 10.1038/s41375-018-0264-0. Epub 2018 Oct 12. Leukemia. 2018. PMID: 30315232
Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.
Shah MV, Chhetri R, Dholakia R, Kok CH, Gangat N, Alkhateeb HB, Al-Kali A, Patnaik MM, Baranwal A, Greipp PT, He R, Begna KH, Tiong IS, Wei AH, Hiwase D. Shah MV, et al. Among authors: kok ch. Am J Hematol. 2022 Aug;97(8):1013-1022. doi: 10.1002/ajh.26589. Epub 2022 May 27. Am J Hematol. 2022. PMID: 35560061 Free PMC article.
A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure.
Kutyna MM, Kok CH, Lim Y, Tran ENH, Campbell D, Paton S, Thompson-Peach C, Lim K, Cakouros D, Arthur A, Hughes T, Kumar S, Thomas D, Gronthos S, Hiwase DK. Kutyna MM, et al. Among authors: kok ch. Leukemia. 2022 Nov;36(11):2678-2689. doi: 10.1038/s41375-022-01686-y. Epub 2022 Aug 29. Leukemia. 2022. PMID: 36038666 Free PMC article.
67 results